Gregory L. Shiferman - 24 Jun 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Senior Vice President, General Counsel and Secretary
Signature: Brandon Marsh, attorney in fact for Gregory L. Shiferman
Issuer symbol: SAGE
Transactions as of: 24 Jun 2025
Net transactions value: -$728
Form type: 4
Filing time: 26 Jun 2025, 16:02:20 UTC
Previous filing: 11 Apr 2025
Next filing: 31 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shiferman Gregory L.	Senior Vice President, General Counsel and Secretary	C/O SAGE THERAPEUTICS, INC., 55 CAMBRIDGE PARKWAY, CAMBRIDGE	Brandon Marsh, attorney in fact for Gregory L. Shiferman	26 Jun 2025	0002041689

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Tax liability	$728	-79	-0.25%	$9.22	30,950	24 Jun 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 24, 2025, the reporting person vested 234 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

Content

On June 24, 2025, the reporting person vested 234 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

Remarks:

Senior Vice President, General Counsel and Secretary